Otsuka Pharmaceutical Acquires Transcend Therapeutics

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Otsuka Pharmaceutical Acquires Mindset Pharma

August 31, 2023

Biotechnology

Otsuka Pharmaceutical Co., Ltd., through its wholly owned U.S. subsidiary Otsuka America, Inc., agreed to acquire Mindset Pharma Inc. in an all-cash statutory plan of arrangement valued at approximately CAD 80 million. The acquisition adds Mindset’s next-generation psychedelic and non-psychedelic drug discovery assets and synthesis capabilities to Otsuka’s psychiatry and neurology pipeline.

Sanofi Acquires Translate Bio in $3.2 Billion Deal

August 3, 2021

Biotechnology

Sanofi SA has entered into a definitive agreement to acquire all outstanding shares of clinical-stage mRNA therapeutics company Translate Bio for about $3.2 billion, or $38.00 per share in cash. The acquisition is intended to accelerate Sanofi’s application of messenger RNA (mRNA) to develop therapeutics and vaccines, building on an existing mRNA collaboration.

Bain Capital to Acquire Mitsubishi Tanabe Pharma in $3.3B Carve-Out

February 7, 2025

Pharmaceuticals

Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The deal values Tanabe Pharma at approximately 510 billion JPY (~$3.3 billion) and is expected to close in the third quarter of 2025, subject to regulatory clearance and approvals.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Chugai Pharmaceutical to Acquire Renalys Pharma

October 24, 2025

Biotechnology

Chugai Pharmaceutical Co., Ltd. will acquire Renalys Pharma, Inc. through a definitive stock purchase agreement. The transaction includes an upfront payment of JPY 15.0 billion and potential earn-outs of up to JPY 16.0 billion tied to regulatory and sales milestones for sparsentan in Japan, South Korea, and Taiwan.